Ozmosi | Estianeptine Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

Estianeptine

Pronounced as: es-tee-uh-nep-teen

Alternative Names: Estianeptine, TNX-4300, TNX4300, TNX 4300
Clinical Status: Active
Latest Update: 2024-05-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Tonix Pharmaceuticals
Company Location: Eastern America
Company Founding Year: 2011
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Central Nervous System Diseases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated